Renaissance Technologies LLC Grows Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Renaissance Technologies LLC raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 142.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 215,431 shares of the medical equipment provider’s stock after buying an additional 126,700 shares during the period. Renaissance Technologies LLC owned about 0.31% of Lantheus worth $17,297,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Silverberg Bernstein Capital Management LLC boosted its position in shares of Lantheus by 0.4% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after buying an additional 100 shares during the period. Moody National Bank Trust Division boosted its position in shares of Lantheus by 1.1% during the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after buying an additional 162 shares during the period. Shaker Investments LLC OH boosted its position in shares of Lantheus by 0.7% during the first quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider’s stock worth $1,740,000 after buying an additional 182 shares during the period. NBC Securities Inc. boosted its position in shares of Lantheus by 28.4% during the first quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock worth $53,000 after buying an additional 191 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 208 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on LNTH. Truist Financial decreased their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. JMP Securities decreased their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. B. Riley lifted their target price on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. Redburn Atlantic began coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company. Finally, Leerink Partners lifted their target price on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Insider Transactions at Lantheus

In other news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now owns 21,221 shares in the company, valued at $2,047,402.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the transaction, the president now owns 98,980 shares in the company, valued at approximately $9,540,682.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 40,852 shares of company stock worth $3,922,001. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Up 1.4 %

Lantheus stock opened at $110.05 on Friday. The stock’s fifty day moving average is $105.51 and its two-hundred day moving average is $84.24. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The stock has a market cap of $7.63 billion, a PE ratio of 16.80 and a beta of 0.50.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same quarter last year, the firm posted $1.40 EPS. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. On average, sell-side analysts expect that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.